Maximus (MMS) to Release Quarterly Earnings on Thursday

Maximus (NYSE:MMS) is projected to post its Q1 2026 results before the market opens on Thursday, February 5th. Analysts expect Maximus to post earnings of $1.84 per share and revenue of $1.3749 billion for the quarter. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, November 20th. The health services provider reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.01). The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.34 billion. Maximus had a net margin of 5.87% and a return on equity of 25.23%. The firm’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.46 EPS. On average, analysts expect Maximus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Maximus Trading Down 2.0%

Maximus stock opened at $94.90 on Thursday. The business has a 50-day simple moving average of $89.63 and a two-hundred day simple moving average of $85.62. The company has a market cap of $5.18 billion, a P/E ratio of 17.07 and a beta of 0.56. Maximus has a 52-week low of $63.77 and a 52-week high of $100.00. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.77.

Maximus Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a $0.33 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Maximus’s previous quarterly dividend of $0.30. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.4%. Maximus’s payout ratio is 21.58%.

Analyst Ratings Changes

A number of brokerages have commented on MMS. Zacks Research raised shares of Maximus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. Weiss Ratings restated a “buy (b-)” rating on shares of Maximus in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. According to data from MarketBeat.com, Maximus has a consensus rating of “Strong Buy”.

Insider Buying and Selling at Maximus

In other news, insider Michelle F. Link sold 4,039 shares of the stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total value of $350,746.76. Following the completion of the sale, the insider directly owned 19,542 shares of the company’s stock, valued at $1,697,027.28. This represents a 17.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Boston Partners raised its holdings in Maximus by 47.0% during the third quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after acquiring an additional 308,892 shares during the period. Bank of America Corp DE grew its position in shares of Maximus by 24.6% during the third quarter. Bank of America Corp DE now owns 453,616 shares of the health services provider’s stock worth $41,447,000 after purchasing an additional 89,693 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in Maximus by 115.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 379,342 shares of the health services provider’s stock valued at $26,630,000 after purchasing an additional 203,521 shares during the period. Wellington Management Group LLP raised its stake in Maximus by 6.3% during the 3rd quarter. Wellington Management Group LLP now owns 374,108 shares of the health services provider’s stock valued at $34,182,000 after purchasing an additional 22,111 shares during the period. Finally, UBS Group AG lifted its holdings in Maximus by 4.6% in the 3rd quarter. UBS Group AG now owns 345,259 shares of the health services provider’s stock worth $31,546,000 after purchasing an additional 15,044 shares in the last quarter. Institutional investors own 97.21% of the company’s stock.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.